Prospective Randomised Trial of First and Second Line Treatments of RCT of First and Second Line H Pylori Treatments in Slovenia

Helicobacter Pylori Infection Clinical Trial

Official title:

Prospective Randomised Trial of First and Second Line Treatments of Helicobacter Pylori Infection in Slovenia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04359966
• Other study ID #: SZGH Krka
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 10, 2020
• Est. completion date: September 30, 2023

Study information

• Verified date: April 2020
• Source: Slovenian Society for Gastroenterology and Hepatology
• Contact: BOJAN TEPES
• Phone: 0038641325916
• Email: bojan.tepes[@]siol.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study is prospective randomised multicentric. The primary objective of the study is to compare the efficacy of two first-line therapy regimens and two second-line therapy regimens (ie, after failure of first-line treatment) in patients with H. pylori infection. The secondary objective of the study is to determine the primary resistance of H. pylori to antibiotics in Slovenia.

Description:

The infection with Helicobacter pylori is extremely widespread, as 60% of the world's population is infected. In Slovenia, the average prevalence is 25.1 %, the prevalence in the 20-year age group is 20 % and 76 % in patients in age group 50 - 75 years. All infected patients have active chronic gastritis, which is asymptomatic in most cases. Ulcers in the stomach or duodenum occurs in 15 % of patients. Due to chronic infection, MALT lymphoma or gastric cancer develop in 1 - 3 % of patients. According to the recommendations of the Slovenian Association for Gastroenterology and Hepatology, as well as European and other recommendations, everyone who is infected with Helicobacter pylori should be treated. H. pylori is a first-class carcinogen and is responsible for 50 % of all chronic cancer-causing infections in the developed world. Therefore, it is necessary to start programs of primary and secondary prevention of gastric cancer by searching and treating infected patients.

Patients infected with H. pylori who have not yet been treated will be randomly assigned to two first-line treatment groups:

Group 1: Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID,14 days Group 2: Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg, all QID Esomeprazole 40 mg BID, 14 days

Patients unsuccessfully treated with first-line therapy will be randomly assigned to two second-line treatment groups:

Group 1: Esomeprazole 40 mg BID, Levofloxacin 500 mg OID, Amoxicillin 1000 mg BID, 14 days Group 2: Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days

Inclusion criteria :

Patients 18 to 80 years of age. Patients have not received proton pump inhibitors for the past 14 days. Patients did not receive antibiotics last month. Helicobacter pylori infection has been demonstrated by rapid urease test

Exclusion criteria :

Prior treatment for Helicobacter pylori infection (in patients who will receive Schedule 1 eradication therapy).

Defects in blood clotting. taking anticoagulant medicines that make it impossible to take biopsies.

Drug allergy used in the study. Pregnancy, breastfeeding. Psychiatric illness that would prevent research participation. Active treatment for malignancy.

Statistical analysis:

To describe the variables, we will use the average value and standard deviation for the symmetrically distributed variables or median and 25th and 75th percentiles for asymmetrically distributed variables. Investigators will use the t-test for dependent variables or, in the case of asymmetrically distributed variables, the Wilcoxon test. To determine the differences between the two groups (Group 1 and Group 2) of the subjects, t-test for independent samples Will be used, or in the case of an asymmetrically distributed variables Mann-Whitney test.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 560
• Est. completion date: September 30, 2023
• Est. primary completion date: May 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria:

• Patients 18 to 80 years of age.

• Patients have not received proton pump inhibitors for the past 14 days.

• Patients did not receive antibiotics in the last month.

• Helicobacter pylori infection has been demonstrated by rapid urease test.

Exclusion Criteria:

• Prior treatment for Helicobacter pylori infection (in patients who will receive Schedule 1 eradication therapy).•

• Defects in blood clotting. taking anticoagulant medicines that make it impossible to take biopsies.

• Allergy to drugs used in the study.

• Pregnancy, breastfeeding shold be excluded.

• Psychiatric illness that would prevent research participation.

• Active treatment for malignancy.

Related Conditions & MeSH terms

• Eradication Treatments
• Helicobacter Infections
• Helicobacter Pylori Infection
• Infection

Intervention

Drug:
• Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,
First line therapy
• Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg
First line therapy second arm
• Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg
Second line therapy for Helicobacter pylori infection
• Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg
Second line therapy for Helicobacter pylori infection second arm

Locations

Country	Name	City	State
Slovenia	DC BLED	Bled
Slovenia	UCC	Ljubljana
Slovenia	Am Dc Rogaska	Rogaška Slatina

Sponsors (2)

Lead Sponsor	Collaborator
Slovenian Society for Gastroenterology and Hepatology	KRKA

Country where clinical trial is conducted

Slovenia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Success rate of first line therapy for Helicobacter pylori infection	Eradication rate	2 years
Primary	Success rate of second line therapy for Helicobacter pylori infection	Eradication rate	3 years
Secondary	Helicobacter pylori resistance rate to antibiotics	Culture and susceptibility testing	3 years